Member Info for Bobat123

Buy printed as unknown. Mms games

Still holding. You only lose if you sell. Will see what happens. Needs RNs to see where we stand and what's going to happen in the future. Gla

Seller out it seems. No big selling during the past few days. Looks like all peeps sitting and waiting on news now.

Greed has put peeps into the situation they are in. Only themselves to blame. Many had chance to sell for profits and did not sell . They are now here and stuck on losses.

All sorts of games getting played here. Need RNs to clarify. Will most probably get one before end of march.

Presentation done during the week. Will be interesting to see if peeps start loading up. Brokers rating over 90.

Will be interesting to see what happens today. Will there be buyers or seller all done now?

Hopefully this should now move

Tr1 Out. Mathew lodge selling out

Crafty mms printing buys as unknown and holding this back

Lisa Anson, Chief Executive Officer, and Peter Collum, Chief Financial Officer, presented in-person at the TD Cowen 44th Annual Health Care Conference in Boston, MA, on Wednesday 6 March at 9:50am ET.

Presentation out from this morning

https://www.redxpharma.com/investor-centre/presentations-analyst-reports-documents-and-videos/

Presentation out from this morning

https://www.redxpharma.com/investor-centre/presentations-analyst-reports-documents-and-videos/

Mms playing games. 40000 buy showing as sell. On here they are showing as unknown trades. Definitely a buy.

("Redx" or the "Company")

Redx to Present at the TD Cowen 44th Annual Health Care Conference

(AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces that Lisa Anson, Chief Executive Officer, and Peter Collum, Chief Financial Officer, will be presenting in-person at the TD Cowen 44th Annual Health Care Conference in Boston, MA, on Wednesday 6 March at 9:50am ET. Alongside the presentation, the Company will also be available for one-to-one meetings.

The presentation will be webcast live and can be accessed via the following link: https://wsw.com/webcast/cowen154/redx.l/2263774

Following the event, a recording will be made available on the investor section of the Company's website at: https://www.redxpharma.com/investor-centre/presentations-analyst-reports-documents-and-videos/

This stock is held very tightly. Conference next week. Broker rating is also over 90. Need patience

12.5 million buy from morning printed. £56k worth.

Option Agreement

29 February 2024

Corcel Plc (London AIM: CRCL), the Angolan-focused exploration and production company, announces that it has been notified that Extractions Premium & Mining Ltd. ("EXT"), which currently holds a 24.37% interest in Corcel, has entered into a Call Option Agreement (the "Option") with Richard Jennings ("RJ").

Under the terms of this agreement, EXT has the right from 1 March 2024 until 1 June 2024, to purchase up to 99,000,000 ordinary shares of the Company from RJ, representing 5.58% of the ordinary shares currently in issue, at a price of £0.012 per share. This price represents a 37% premium to the most recent closing price of the Company's shares.

The Option contains an auto-exercise function, such that it will be deemed to have been exercised if the shares trade over £0.015 as measured on a VWAP basis for five consecutive trading days and in an aggregate minimum volume of 20,000,000 shares.

As previously announced, EXT is 45% owned by the Executive Chairman of Corcel Plc, Antoine Karam, and as such Antoine will indirectly hold 194,649,761.

Over 75million buys during the last week. Peeps can move on if they wish. Follow the money. Tr1 coming soon

First Participant Dosed in Phase 1 Clinical Trial for RXC008

Potential first-in-class GI-targeted ROCK inhibitor for fibrostenotic Crohn's disease enters Phase 1 study

RXC008 is the second wholly-owned asset from Redx's ROCK portfolio to enter clinical development

Alderley Park, UK, 28 February 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces that the first participant has been dosed in a Phase 1 clinical trial for RXC008. RXC008 is a wholly-owned gastro-intestinal (GI) targeted Rho Associated Coiled-Coil Containing Protein Kinase (ROCK) inhibitor, being developed as a potential first-in-class treatment for patients with fibrostenotic Crohn's disease. The primary objective of this first-in-human study is to evaluate the safety and pharmacokinetic (PK) profile of the drug and it is expected that results from the healthy volunteer cohorts will be available by the end of 2024.

Lisa Anson, Chief Executive Officer, Redx Pharma commented: "We are delighted to confirm that the first participant has been dosed in the RXC008 Phase 1 clinical study. RXC008 is a potential first-in-class treatment for patients with fibrostenotic Crohn's disease, a debilitating condition where successive surgeries are the only treatment option available today. This milestone represents the sixth asset from Redx to enter clinical development, continuing our strong track record in small molecule drug discovery as a result of our world-class medicinal chemistry and translational science expertise."

Code 1 printed for the believers. RNs due